Thai PBS Thai PBS
Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market

Pfizer, Moderna seen reaping billions from COVID-19 vaccine booster market

13 Sept 14:09 Key points summarised by AI
  • Pfizer, BioNTech, and Moderna are poised to earn billions from COVID-19 booster shots, with the market expected to rival the annual $6 billion flu vaccine sales.
  • The demand for boosters is driven by evidence of waning immunity, the rapid spread of the Delta variant, and initial government authorizations for vulnerable groups.
  • Analysts project substantial booster sales for these companies in 2023 and beyond, following over $60 billion in initial vaccine sales secured for 2021-2022.
  • The long-term market will see increasing competition and potential government intervention in pricing, similar to the established flu shot market, though initial pricing power for Pfizer and Moderna remains strong.
Read full article
Economy 1/2
Skip > Skip >